ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer
Lora Stojanovic,Rachel Abbotts,Kaushlendra Tripathi,Collin M Coon,Saranya Rajendran,Elnaz Abbasi Farid,Galen Hostetter,Joseph W Guarnieri,Douglas C Wallace,Sheng Liu,Jun Wan,Gennaro Calendo,Rebecca Marker,Zahra Gohari,Mohammed M A Inayatullah,Vijay K Tiwari,Tanjina Kader,Sandro Santagata,Ronny Drapkin,Stefan Kommoss,Jacobus Pfisterer,Gottfried E Konecny,Ryan Coopergard,Jean-Pierre Issa,Boris J N Winterhoff,Michael J Topper,George E Sandusky,Kathy D Miller,Stephen B Baylin,Kenneth P. Nephew,Feyruz V Rassool
DOI: https://doi.org/10.1101/2024.10.18.618659
2024-10-21
Abstract:DNA methyltransferase and poly(ADP-ribose) polymerase inhibitors (DNMTis, PARPis) induce a stimulator of interferon (IFN) genes (STING)-dependent pathogen mimicry response (PMR) in ovarian (OC) and other cancers. We now show that combining DNMTis and PARPis upregulates expression of a little-studied nucleic-acid sensor, NFX1-type zinc finger-containing 1 protein (ZNFX1). We demonstrate that ZNFX1 is a novel master regulator for PMR induction in mitochondria, serving as a gateway for STING-dependent PMR. In patient OC databases, high ZNFX1 expression levels correlate with advanced stage disease. ZNFX1 expression alone significantly correlates with an increase in overall survival in a phase 3 trial for therapy-resistant OC patients receiving bevacizumab in combination with chemotherapy. In correlative RNA-seq data, inflammasome signaling through ZNFX1 correlates with abnormal vasculogenesis. ZNFX1 controls PMR signaling through the mitochondria and may serve as a biomarker to facilitate offering personalized therapy in OC patients, highlighting the strong translational significance of our findings.
Cancer Biology